Web19 ott 2024 · "These results from the NETTER-1 study continue to show that Lutathera delivers strong efficacy in patients with a challenging disease burden," said Samit Hirawat, MD, Head of Novartis Oncology Global Drug Development. "Demonstrating improved PFS and maintenance of QoL in patients with neuroendocrine tumors with poor prognosis due … Web18 nov 2024 · Furthermore, PFS, combining with high-concentration formulations, can also bring advantages such as patient compliance, dosing accuracy and reduction of wasted drug. Both greater dose precision and minimizing the drug waste can lead to smaller overage requirement, then further result in cost savings ( 45–47 ).
PFS and Autoinjector Drug Delivery: A Platform of Primary …
Web21 apr 2024 · Citation: Gupta S, “Drug Delivery to the Eye: Overcoming the Challenges of Intravitreal Prefilled Syringes”. ONdrugDelivery, Issue 118 (Apr 2024), pp 18–21. Suresh Gupta discusses the challenges of developing a PFS product for intravitreal injection, highlighting how designing for the intravitreal space, rather than the standard parenteral, … WebPFS is simply a measure of a drug's effect on tumor growth while it is administered and is not a surrogate for OS. Although PFS should not replace OS in regulatory approval consideration should be given to studies that treat beyond current definitions of progressive disease as a strategy to augment OS. psychotic beats
a PFS end point is not sufficient - Nature
Web(PFS), increased in the application for new oncology drug approval; in particular ORR with or without TTP was used in almost 50% of the application (from Jan 90 to Nov 2002) [1]. SURROGATE ENDPOINTS A “surrogate endpoints” is an alternative endpoint (e.g. biological markers, physical sign, etc.) that if validated allows Web21 dic 2024 · One of the major reasons why depressed patients fail their treatment course is the existence of the blood-brain barrier (BBB), which prevents drugs from being delivered to the central nervous system (CNS). In recent years, nasal drug delivery has achieved better systemic bioavailability and activity in low doses in antidepressant treatment. In this … Web12 apr 2024 · The primary scientific question of interest of this study is whether the combination of ociperlimab, tislelizumab and chemotherapy improves progression-free survival (PFS) compared to the combination of placebo, pembrolizumab and chemotherapy as first-line therapy for adult men and women with advanced triple negative breast … hot books to read